The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Turner William D. since 2022.
This trader's CIK number is 1819688.
At the time of last reporting, Turner William D. was the Chief Regulatory Officer of Vera Therapeutics, Inc.. (stock ticker symbol VERA).
Also see all insider trading activities at Vera Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | SRRA | 0 | $0 | 15,000 | $507,023 | 15,000 | $180,749 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | VERA | 0 | $0 | 10,000 | $400,000 | 10,000 | $155,300 |
1. Sierra Oncology, Inc. (SRRA)
2. Vera Therapeutics, Inc. (VERA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-04-05 | SRRA | Option Ex | 100 | 12.05 | 1,205 |
| 2022-04-06 | SRRA | Option Ex | 6,347 | 12.05 | 76,481 |
| 2022-04-05 | SRRA | Sale | 100 | 37.09 | 3,709 |
| 2022-04-06 | SRRA | Sale | 6,347 | 37.25 | 236,406 |
| 2022-03-18 | SRRA | Option Ex | 100 | 12.05 | 1,205 |
| 2022-03-18 | SRRA | Sale | 100 | 37.05 | 3,704 |
| 2022-03-17 | SRRA | Option Ex | 3,453 | 12.05 | 41,608 |
| 2022-03-17 | SRRA | Sale | 3,453 | 37.06 | 127,954 |
| 2022-01-26 | SRRA | Option Ex | 5,000 | 12.05 | 60,250 |
| 2022-01-26 | SRRA | Sale | 5,000 | 27.05 | 135,250 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-12-03 | VERA | Option Ex | 10,000 | 15.53 | 155,300 |
| 2025-12-03 | VERA | Sale | 10,000 | 40.00 | 400,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Turner William D. (Chief Regulatory Officer of Vera Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.